The Endpoints 100 survey: Has biotech hit rock bottom?

There may be a solid chunk of executives in the Endpoints 100 who feel that better times are ahead for the biotech industry in 2024, but they’re still outnumbered by doubters and the undecided.

This H2 snapshot of the opinions of 100+ biotech execs — the large majority of CEOs…
Click here to view original post